MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

4.240 -0.430 (-9.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗
The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued. 
Via Stocktwits
News headline image
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗
Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 
Via Stocktwits
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators. 
Via Benzinga
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Unusual volume stocks are being observed in Monday's session. ↗
These stocks have an unusual volume in today's session 
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
11 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Crude Oil Dips 7%; ISM Services PMI Falls In March ↗
 
Via Benzinga
News headline image
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic ↗
Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with... 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
News headline image
These stocks that are showing activity before the opening bell on Thursday. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall ↗
 
Via Benzinga
Topics Stocks
News headline image
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns ↗
The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30% ↗
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission. 
Via Benzinga
News headline image
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 ↗
ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying ↗
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study ↗
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in  
Via Benzinga
News headline image
3 Stocks at the Forefront of Personalized Medicine Trend ↗
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly 
Via InvestorPlace
News headline image
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study ↗
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reproxalap, an investigational drug  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story